Companies poised to take Chinese checkpoints global

Three companies poised to answer Pazdur’s call for Chinese PD-1 inhibitors

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price.

Two Chinese drugmakers and one U.S. company globally developing therapies from China have plans underway to bring Chinese PD-1 inhibitors to the U.S.

Shanghai Junshi Biosciences Co. Ltd. and Innovent Biologics Inc. each market domestically developed PD-1 inhibitors in China, and each have U.S. development plans that should lead to discounted products.

In China, both of the anti-PD-1 mAbs are priced below Keytruda pembrolizumab from Merck & Co. Junshi sells Tuoyi toripalimab at an 83% discount, and Innovent Biologics Inc. sells Tyvyt sintilimab (IBI308) at a 56% discount.

Behind them is Apollomics Inc., a Bay Area-based company whose mission is to globalize Chinese innovations. Apollomics is working out U.S. development plans for its anti-PD-1 mAb APL-501, which is in Phase II testing in China through its partner Genor Biopharma Co. Ltd., a subsidiary of

Read the full 1590 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers